News

Dan Proft used his Chicago’s Morning Answer program to spotlight Charcot-Marie-Tooth disease (CMT), a progressive genetic nerve disorder that affects roughly one in 2,500 people. The segment, tied to an upcoming charity golf outing at the Merit Club in Libertyville, featured Cure CMT founder Patrick Livney, who has lived with the condition since his teens. CMT is named for the three doctors who first described it in the late 1800s. It impacts the peripheral nerves that control movement and sensation…

Join us for the Cure CMT Golf Challenge at Merit Club, in Libertyville, IL, Monday, August 18, 2025. Cure CMT is making a difference by funding leg braces and surgeries for CMT patients, dramatically improving their mobility and quality of life. Cure CMT is also investing in the promising technologies BIO-Pharma has to offer to accelerate the path toward a first treatment/cure! Merit Club 1500 Merit Club Lane Libertyville, IL 60064 10:30 am arrival time Register now

Chicago, Illinois July 8, 2025 – Cure CMT, a leading advocacy organization dedicated to finding treatments and cures for Charcot-Marie-Tooth disease, today announced a significant partnership with Tamarack Habilitation Technologies, Inc., a Minnesota-based leader in orthotic and prosthetic innovation. Through this collaboration, Tamarack has provided a generous investment to support Cure CMT's mission while making their advanced orthotic products directly accessible to CMT patients through Cure CMT's website platform. Charcot-Marie-Tooth disease affects approximately 1 in 2,500 people worldwide, causing progressive muscle…

A new clinical trial is offering hope for people with Charcot-Marie-Tooth (CMT) disease. Researchers tested a plasmid-based gene therapy designed to support nerve and muscle function. Unlike viral gene therapies, this treatment can be given multiple times without triggering an immune response—making it a promising option for chronic conditions like CMT. In a small Phase 1 trial in Seoul, South Korea, 12 participants with CMT type 1A received injections of the therapy over 104 days. The results? No serious side…